Concepedia

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial

Elizabeth K. Lee, Niya Xiong, Su–Chun Cheng, William T. Barry, Richard T. Penson, Panagiotis A. Konstantinopoulos, Mark A. Hoffman, Neil S. Horowitz, Don S. Dizon, Elizabeth H. Stover,

Gynecologic Oncology · 2020 · 89 citations · 33 references

DOI

Concepts

References

33

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers, Jared Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation · 2017 · 3.9K citations · Full text

, , +17

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Lin Zhang, José R. Conejo-García, Dionyssios Katsaros et al. · New England Journal of Medicine · 2003 · 3.4K citations · Full text

, , +17

Calreticulin exposure dictates the immunogenicity of cancer cell death

Michel Obéid, Antoine Tesnière, François Ghiringhelli et al. · Nature Medicine · 2006 · 3.1K citations

, , +14

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

, , +17

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 <sup>+</sup> T lymphocytes are prognostic factors of human ovarian cancer

Junzo Hamanishi, Masaki Mandai, Masashi Iwasaki et al. · Proceedings of the National Academy of Sciences · 2007 · 1.4K citations · Full text

, , +17